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The delayed diagnosis of tuberculous meningitis (TBM) leads to poor outcomes, yet the current diagnostic methods for identifying 
Mycobacterium tuberculosis in cerebrospinal fluid (CSF) are inadequate. The first comparative study of the new GeneXpert MTB/
RIF Ultra (Xpert Ultra) for TBM diagnosis suggested increased sensitivity of Xpert Ultra. Two subsequent studies have shown Xpert 
Ultra has improved sensitivity, but has insufficient negative predictive value to exclude TBM. Collecting and processing large vol-
umes of CSF for mycobacterial testing are important for optimal diagnostic test performance. But clinical, radiological, and labo-
ratory parameters remain essential for TBM diagnosis and empiric therapy is often needed. We therefore caution against the use of 
Xpert Ultra as a single diagnostic test for TBM; it cannot be used to “rule out” TBM.
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Tuberculous meningitis (TBM) is the most severe form of tuber-
culosis (TB), leading to death in 30–50% of individuals despite 
treatment [1–4]. Early diagnosis of TBM is vital and delayed di-
agnosis leads to poor clinical outcomes [5]. Confirming a TBM 
diagnosis requires identification of Mycobacterium tuberculosis 
(Mtb) in cerebrospinal fluid (CSF). However, unlike sputum 
in pulmonary TB, there are few bacteria in the CSF, and Mtb 
detection is often challenging. Conventional TBM diagnosis 
depends upon CSF Ziehl-Neelsen (ZN) smear microscopy to 
detect acid-fast bacilli (AFB), CSF mycobacterial culture, and, 
if available, detection of mycobacterial DNA in CSF. Each test 
modality has advantages and limitations. Ziehl-Neelsen smear 
microscopy can be performed quickly and requires minimal 
specialist equipment, yet it is often insensitive and true positive 
cases are frequently missed [6]. ZN smear sensitivity is influ-
enced by CSF processing steps and microscopist expertise, with 
sensitivities of usually 10–50% [7–9] and rarely higher [10, 11]. 
Mycobacterial culture, when positive, allows drug susceptibility 
testing; however, results are usually not available for at least 2 
weeks, too late to guide early anti-TB chemotherapy. In contrast, 
fully automated polymerase chain reaction (PCR) testing with 
Xpert MTB/RIF (Xpert) testing using the GeneXpert platform 
(Cepheid, Sunnyvale, CA) can generate results in under 2 hours 
and, if positive, includes rifampicin resistance prediction. While 
generally cheaper than culture techniques, the Xpert per car-
tridge cost is approximately $10 in countries eligible for con-
cessional pricing, and cartridge provision remains heavily 
supported by donor organizations in many settings. In recent 
TBM studies [9, 11–14], sensitivity of mycobacterial culture 
ranged from 26% to 67%, and sensitivity of Xpert ranged from 
18% to 59%. Xpert has been rapidly adopted worldwide largely 
due to its speed and ease of use allowing for reduced reliance 
upon time-consuming smear microscopy by experienced tech-
nicians. While some training is required to run the Xpert in-
strument, much less expertise and time are required than are 
needed to accurately diagnose TBM by smear microscopy—few 
in the world have mastered this skill. Neither of these tests is 
adequate for TBM diagnosis, and so a high degree of clinical 
suspicion and a low threshold to initiate empiric anti-TB che-
motherapy are crucial to successful outcomes from TBM treat-
ment. All currently available diagnostic tests for TBM rely on 
CSF sampling, which presents a barrier to improving TBM di-
agnosis, as CSF sampling may be delayed, unavailable or contra-
indicated in some settings.
To address limitations with Xpert for TB diagnosis, the Xpert 
MTB/RIF Ultra (Xpert Ultra) cartridge was developed [15]. 
Modifications in the Xpert Ultra cartridge include a larger re-
action chamber to double the amount of sample, and thereby 
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amplification target genes (IS6110 and IS1081) [15]. In contrast 
to the single rpoB gene, the IS6110 and IS1081 genes appear in 
variable numbers between Mtb lineages and within a single lin-
eage [15, 16]. These cartridge modifications aimed to improve 
diagnostic sensitivity and improve reliability of rifampicin-
resistance detection. In vitro, the lower limit of detection de-
creased to approximately 16 colony forming units (CFU)/mL 
from approximately 100–120 CFU/mL for Xpert, similar to cul-
ture (~10 CFU/mL) [15].
Complicating efforts to improve TBM diagnosis is the fact 
that no single reference “gold standard” test exists. Typically, 
new tests are measured against mycobacterial culture alone, 
composite reference standards (positive ZN smear microscopy, 
Xpert or mycobacterial culture), or consensus clinical case def-
initions [17]. A  composite reference standard may represent 
all microbiologically confirmed TBM, not just that confirmed 
by mycobacterial culture, as culture is known to be only mod-
erately sensitive. Inclusion of Xpert Ultra (the index test) in a 
composite reference standard aims to more accurately estimate 
Xpert Ultra sensitivity (ie, it allows samples positive only by 
Xpert Ultra to be in the reference standard, with an assump-
tion that the likelihood of false-positive Xpert Ultra tests is very 
low). However, Xpert Ultra specificity cannot be assessed with 
this approach (specificity would always be 100%; all tests would 
be true positives). Each reference standard has its own issues 
and presenting a combination of these possibilities gives the 
reader the most complete picture of test performance, albeit 
with caveats. Regardless of the standard(s) used, it is clear that 
cases of TBM are being missed with currently available diag-
nostic tests. It is against this range of reference standards that 
Xpert Ultra has been evaluated.
The World Health Organization (WHO) recommended that 
Xpert Ultra replace Xpert in all settings in March 2017 [18]. 
This followed on from a 2014 WHO Xpert implementation 
manual [19], which strongly recommended that “Xpert should 
be used in preference to conventional microscopy and culture 
as the initial diagnostic test for cerebrospinal fluid (CSF).” After 
the 2014 WHO recommendation regarding Xpert for TBM, the 
Tuberculous Meningitis International Research Consortium 
authored a statement conveying that, while it was reasonable to 
use Xpert as the first test for TBM, it should not be the last test, 
as Xpert was not sufficiently accurate to “rule out” TBM [20].
The initial study of Xpert Ultra for TBM diagnosis was prom-
ising. Among 129 Ugandan adults with human immunodefi-
ciency virus (HIV) with suspected meningitis (23 with definite 
or probable TBM), diagnostic sensitivities of Xpert Ultra, Xpert, 
and mycobacterial culture were 69.6% (95% confidence interval 
[CI], 47.1–86.8%), 43.5% (95% CI, 23.2–65.5%), and 43.5% 
(95% CI, 23.2–65.5%) [14]. Against a composite microbiolog-
ical reference standard (Xpert, culture, or Xpert Ultra), Xpert 
Ultra sensitivity was 95.5% versus 45.5% for culture or Xpert. 
Importantly, even in the best-case scenario (the composite 
microbiological reference standard), Xpert Ultra did not detect 
all TBM cases.
In January 2020, 2 larger prospective studies evaluating Xpert 
Ultra were published. In the study by Cresswell et al [13], 204 
Ugandan adults (96% coinfected with HIV) with suspected 
meningitis had CSF Xpert Ultra performed. Compared with 
a reference of definite or probable TBM, test sensitivities were 
76.5% (95% CI, 62.5–87.2%) for Xpert Ultra, 55.6% (95% CI, 
44.0–70.4%) for Xpert, and 61.4% (95% CI, 45.5–75.6%) for my-
cobacterial culture. In this study “possible TBM” cases were not 
included in the reference standard as this category is nonspe-
cific in HIV coinfection due to concomitant brain pathologies 
associated with advanced immunosuppression. In the second 
study, Donovan et al [12] randomized 205 Vietnamese adults 
(15% coinfected with HIV) with meningitis to either Xpert 
Ultra or Xpert testing. Against a reference standard of definite, 
probable, or possible TBM, test sensitivities were 47.2% (95% 
CI, 34.4–60.3%) for Xpert Ultra, 39.6% (95% CI, 27.6–53.1%) 
for Xpert, and 47.9% (95% CI, 38.0–57.9%) for mycobacterial 
culture. As with Xpert [11], specificity of Xpert Ultra for TBM 
diagnosis was high in both studies [12, 13]. Xpert Ultra sensi-
tivity was statistically superior to that of Xpert in Uganda but 
not in a predominantly HIV-negative Vietnam population. The 
TBM diagnostic studies using Xpert Ultra are summarized in 
Table 1.
What can be learned from these studies? First, diagnostic 
tests cannot be expected to perform identically in all set-
tings. Differences in tested CSF volume, CSF processing, HIV 
coinfection, genetics influencing host response to Mtb, and 
Mtb lineages could all contribute to these different results, as 
could the differences in study design (eg, dividing specimens 
among the tests vs randomizing samples) and smear micros-
copy sensitivity. Second, regardless of the differences in the 
exact performance of Xpert Ultra, the most important point 
is that, while Xpert Ultra seems to be some improvement on 
Xpert, its negative predictive value is not sufficiently high to ex-
clude TBM when the result is negative. Following on from the 
opinion piece published by Bahr et al [20] in 2016, we wish to 
caution against the use of Xpert Ultra or Xpert as single diag-
nostic tests for TBM. Focus should be placed on collecting and 
processing large volumes of CSF (>6 mL, just for mycobacterial 
testing), maximizing the number of Mtb bacteria in the tested 
sample, and improving chances of confirming a diagnosis of 
TBM. Centrifugation of CSF (3000 g for 15 minutes) concen-
trates Mtb in the pellet and improves diagnostic sensitivity [8]. 
To optimize the performance of ZN smear microscopy, an ap-
propriate time should be spent reading CSF smear slides before 
considering them negative. Microscopist skill and experience 
are hugely important, although they are hard to quantify.
Clinical, radiological, and laboratory parameters remain essen-
tial. Symptoms of meningitis for more than 5 days [17] should lead 
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Chest radiograph may demonstrate miliary or pulmonary TB, 
and brain imaging may show evidence of cerebral infarcts, basal 
meningeal enhancement, or hydrocephalus. Where CSF testing 
fails, diagnostic testing of other potentially involved sites may 
provide microbiological evidence of TB elsewhere. For example, 
sputum Xpert may detect Mtb, or urine TB-lipoarabinomannan 
(TB-LAM) may provide evidence of disseminated TB in patients 
coinfected with HIV. Lymphocytic, low-glucose, high-protein 
CSF is classically seen in TBM but is not always present and exclu-
sion of cryptococcal meningitis is essential in immunosuppressed 
patients [25]. Repeat lumbar puncture after 48–72 hours may be 
valuable in patients who fail to improve with routine antibiotics, 
or in whom diagnosis remains unclear.
Tuberculous meningitis remains a devastating disease, and 
advances in the diagnostic field are being made. While Xpert 
Ultra represents a step forward in TBM diagnosis, Xpert Ultra 
cannot fully exclude this disease. Host biomarkers and an-
tigen detection from CSF may have a future role in TBM di-
agnosis, but more studies are needed [26, 27]. Studies of Xpert 
Ultra for the diagnosis of pediatric TBM are also needed. The 
Tuberculous Meningitis International Research Consortium, 
which includes clinicians, basic scientists, and clinical pharma-
cologists, continues to meet regularly, most recently in March 
2019 in Lucknow, India, to advance the TBM research and 
policy agenda [28]. Policy makers, while adopting improved 
technologies, must resist the temptation to point to any single 
test as a perfect tool. It is crucial that while adopting Xpert 
Ultra, clinicians keep in mind that this test is not perfect and 
cannot “rule out” TBM. The search for new and improved diag-
nostic tests must go on.
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Table 1. Summary of Tuberculous Meningitis Diagnostic Studies Using Xpert MTB/RIF Ultra
First Author, Year of 




 (No. of TBM Cases)





Donovan et al [12], 
2020
Vietnam Randomised, prospective  
diagnostic study of  
meningitis suspects
25 (27/108) Definite, probable, possible 
TBM (n = 108)
47 (25/53) 61 (44/72)
Definite, probable TBM 
(n = 88)
58 (25/43) 75 (54/72)
Definite TBM (n = 82) 60 (25/42) 76 (55/72)
Positive mycobacterial culture 
(n = 45)
91 (20/22) 97 (62/64)
Cresswell et al [13], 
2020
Uganda Prospective cohort of  
meningitis suspects 
98 (50/51) Definite, probable TBM 
(n = 51)
77 (39/51) 93 (153/165)
98 (41/42) Composite microbiologic 
standard (n = 42)
93 (39/42) 98 (153/156)
Wang et al [21], 2019 China Prospective cohort in  
paucibacillary TB  
(inclusive of TBM)a
0 (0/43) Definite, probable, possible 
TBM (n = 43)




Bahr et al [14], 2018 Uganda Prospective cohort with  
retrospective CSF  
testing of meningitis  
suspects
100 (23/23) Definite, probable TBM 
(n = 23)
70 (16/23) 94 (100/107)
Composite microbiologic 
standard (n = 22)
96 (21/22) 99 (106/107)
Wu et al [22], 2019 China Prospective diagnostic  
study in extrapulmonary  
TB (inclusive of TBM)a
0 (0/16) Composite microbiologic 
standard (n = 16)
13 (2/16) NA
Chin et al [23], 2019 Uganda Case series of testing in  
suspected TBM
18 (2/11) Suspected TBM (n = 11) 64 (7/11) NA
Perez-Risco et al [24], 
2018
Spain Evaluation of smear-negative 
extrapulmonary samples  
(inclusive of TBM)a
Not stated Positive mycobacterial culture 
(n = 3)
100 (3/3) NA
Abbreviations: CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; NA, not available; TB, tuberculosis; TBM, tuberculous meningitis.
aFor studies of paucibacillary or extrapulmonary TB, data shown only for TBM cases. Definite, probable, or possible TBM defined per the research uniform case definition [17]. Composite 
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